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Abstract 51 
Background: The impact of ICD shock on device-measured activity and patient reported 52 
outcomes is unknown.     53 
Objective: The purpose of this study was to analyze the acute and long-term effects of ICD 54 
shock on objective behavioral data (i.e., device-based physical activity) and subjective patient 55 
reported outcomes (e.g., quality of life and shock anxiety). 56 
Methods: The PainFree SST clinical trial included 2,770 patients with a single or dual-57 
chamber ICD, or cardiac resynchronization defibrillator (CRT-D) who were followed for 22 58 
± 9 months. Participants completed measures of quality of life (EuroQol 5-D [EQ5D]) and 59 
shock anxiety (Florida Shock Anxiety Scale [FSAS]) at baseline, bi-annual visits, and 60 
monthly for 6 months following an ICD shock. Daily physical activity data were obtained 61 
from a built-in device accelerometer. 62 
Results: Average daily activity was 185.3 ± 119.4 minutes/day. Activity was significantly 63 
reduced after an ICD shock (p<0.0001) and recovered to a normal level after approximately 64 
90 days. ICD shock was also associated with decreased quality of life (EQ5D Health Score) 65 
and increased EQ5D anxiety scores, but it did not impact mobility, self-care, activity, or pain. 66 
Similarly, shock anxiety (FSAS) increased in shocked patients and remained significantly 67 
elevated at 24 months, regardless of appropriate or inappropriate shock delivery.   68 
Conclusions:  ICD shocks have a long-lasting, adverse impact on both objective, device-69 
measured physical activity and subjective patient reported outcomes of quality of life and 70 
shock anxiety. Successful management of ICD patients requires attention to clinically 71 
relevant behavioral and psychological outcomes to expedite recovery and return to activities 72 
of daily living.  73 
Key words:  Quality and Outcomes, Electrophysiology, Mental Health, Exercise, Quality of 74 
Life, Implantable Cardioverter Defibrillator 75 
Clinical Trial Registration: URL: http://clinicaltrials.gov Unique Identifier: NCT00982397 76 
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Introduction 77 
The implantable cardioverter defibrillator (ICD) reduces mortality in patients at risk 78 
for life-threatening arrhythmias.1 However, the fear of experiencing spontaneous arrhythmias 79 
and frequent device-delivered shock therapies may lead some patients to limit their daily 80 
activities or avoid physical exertion, which could adversely impact their health and quality of 81 
life.2    82 
Previous studies of health-related quality of life in ICD patients have generally relied 83 
on subjective, self-report data that is susceptible to recall bias. Results from these studies 84 
have found that while ICD shocks are associated with increased anxiety in smaller, single-85 
institution studies, this is not uniformly the case in larger multicenter trials, suggesting a need 86 
for improved methodology and precision measurement of the effect of ICD shock on the 87 
patient experience.3, 4 Objective behavioral data associated with ICD shock has also been 88 
lacking despite the fact that modern ICDs are capable of collecting longitudinal physical 89 
activity data. Device-measured physical activity has been associated with mortality and 90 
hospitalization,4-6 and could be combined with subjective patient outcomes to provide a more 91 
robust examination of the impact of ICD shock on patient activity and quality of life.  92 
In this study, we analyzed data from the PainFree SST clinical trial to prospectively 93 
examine the acute and long-term effects of ICD therapies on daily activity, quality of life, and 94 
shock anxiety. 95 
Methods 96 
Study Overview and Patient Population  97 
PainFree SST was a large multicenter clinical trial designed to evaluate improved 98 
device detection algorithms to reduce ICD shock (SmartShock® technology). The study 99 
design and primary results have been published elsewhere.7, 8 In brief, PainFree SST enrolled 100 
2,790 patients from 150 centers worldwide implanted with a Medtronic Protecta® (Medtronic 101 
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plc, Minneapolis, MN, USA) single or dual-chamber ICD, or cardiac resynchronization 102 
defibrillator (CRT-D), between September 2009 and August 2012. This included new 103 
implants, upgrades, and replacements. Twenty patients were subsequently excluded from all 104 
analyses for various reasons, resulting in a final study cohort of 2,770 patients. All patients 105 
provided written informed consent. Study protocols and procedures were approved by the 106 
ethics committee or institutional review board at all participating sites. 107 
Data Collection 108 
Patients were seen at enrollment (at the time of ICD implant prior to hospital 109 
discharge) and twice annually thereafter. Device data on patient activity and arrhythmia 110 
episodes treated with a shock or anti-tachycardia pacing (ATP) were extracted. Available 111 
electrocardiograms were reviewed and adjudicated by an independent episode review 112 
committee (ERC). Shock anxiety and quality of life data were collected at baseline, bi-annual 113 
visits, and monthly for 6 months following an ICD shock. This intensive follow-up approach 114 
allowed for closer examination of the immediate and long-term effects of ICD shock from the 115 
patient’s perspective.  116 
Measures 117 
Patient activity data were obtained from the internal ICD accelerometer located in the 118 
device generator. As the body moves, internal sensors generate an electrical signal that is 119 
proportional to acceleration of the generator. A proprietary algorithm interprets the electrical 120 
signal and classifies each minute as active or non-active. The algorithm is calibrated to detect 121 
walking at a slow pace as active. A daily summary score for total activity in minutes per day 122 
is automatically calculated and stored in the device.  The use of device-detected 123 
accelerometer data has been validated as an objective measure of daily activity in previous 124 
studies of ICD patients.6, 9-11  125 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
6 
 
Quality of life was assessed with the EuroQol 5-D (EQ5D) questionnaire, a five-126 
dimension measure of perceived health status (mobility, self-care, usual activities, 127 
pain/discomfort, and anxiety/depression) based on a three-point response (no problems, some 128 
problems, extreme problems). Additionally, the EQ5D includes a visual analog scale (VAS) 129 
which provides a composite health status score referred to as the EQ5D Health Score. Higher 130 
EQ5D Health Scores indicate better self-reported health.  131 
Shock anxiety was assessed with the Florida Shock Anxiety Scale (FSAS), a 10-item 132 
validated, widely used measure of ICD-specific adjustment that assesses feared stimuli and 133 
avoidance behaviors (e.g., “I am scared to exercise because it may increase my heart rate and 134 
cause my device to fire”).5 Respondents rated items on a five-point scale. Items were summed 135 
according to scoring guidelines to obtain a total score ranging from 10 to 50, with higher 136 
values indicating greater shock anxiety. FSAS questionnaires were included in the analysis 137 
when at least 7 of the 10 questions were answered. For questionnaires with missing answers 138 
the summary score was normalized by multiplying with 10/(number of answered questions). 139 
Statistics 140 
Quality of life was prospectively defined as a secondary objective in PainFree SST. 141 
Activity was later added as an outcome parameter. 142 
Categorical parameters are presented with count and percentage, or percentage alone. 143 
For statistical comparison between two groups, a Fisher’s exact test or a Cochran-Mantel-144 
Haenszel test for trend was used. Continuous parameters are presented with mean value and 145 
standard deviation, and compared between groups using a Student’s t-test.  146 
Daily activity records for all patients included device type, time since implant, being 147 
hospitalized (yes/no), experienced earlier shocks (yes/no), and time since most recent shock. 148 
Analysis of activity used linear mixed regression models with daily values as unit of analysis. 149 
These had a random intercept for patient and an auto-regressive structure for correlation of 150 
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subsequent measurements from individual patients. A sandwich variance estimator was used 151 
as an additional correction for repeated measurements in patients. A base model included 152 
device type and time since implant as a piecewise linear covariate with knots at selected time-153 
points post-implant (30, 60, 90, and 365 days post-implant). Follow-up data were restricted to 154 
the first 24 months. Subsequent analyses were done adding variables to the base model. The 155 
effect of hospitalization was estimated as the average difference in activity between days 156 
hospitalized and days not hospitalized, corrected for device type and time since implant. The 157 
effect of ICD shocks was assessed from an indicator variable identifying whether or not there 158 
was an earlier shock and a piecewise linear covariate for time since shock with knots at 30, 159 
60 and 90 days post-shock. The effect of ATP was analyzed similarly. Analyses of the effect 160 
of shocks and ATP were corrected for device type, time since implant, and the effect of 161 
hospitalization. Effects are reported with 95% confidence intervals (CI). 162 
Analysis of FSAS and EQ5D Health Score used a similar modeling approach with 163 
patient visit as the unit of analysis, using a compound symmetry correlation structure. Local 164 
regression (LOESS) was used for the figures. Statistical analysis of the different dimensions 165 
of EQ5D before and after shock used ordinal logistic regression models with GEE variance 166 
adjustment that included all questionnaires from baseline and scheduled follow-up visits with 167 
an indicator variable for earlier shocks. 168 
All analyses were done in SAS version 9.4 (SAS Institute, Cary, NC, USA). P-values 169 
<0.05 were considered significant. 170 
Results 171 
Baseline Characteristics 172 
A total of 2,770 patients were followed for 22 ± 9 months. Clinical characteristics of the 173 
patients are shown in Table 1. ICD shock was more prevalent among patients who were male, 174 
implanted for secondary prevention, taking anti-arrhythmic drugs, or had a prior history of 175 
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atrial fibrillation (AF). Compared to patients with only appropriate shocks, patients with any 176 
inappropriate shock were more likely to have a history of AF, and less likely to have a history 177 
of coronary artery disease, atrioventricular block, coronary artery bypass grafting, or 178 
myocardial infarction. 179 
In total, 915 arrhythmic episodes were extracted from device memory, in which 289 180 
patients received ICD shocks (0.21 episodes per patient year). This included 804 episodes for 181 
which electrocardiograms were available and that were adjudicated: 115 inappropriately 182 
shocked episodes in 70 patients and 689 appropriately shocked episodes in 234 patients. 183 
Additionally, there were 111 shocked episodes in 17 patients where electrocardiograms were 184 
not available due to limited device memory. For 15 of these 17 patients, there were other 185 
shocked episodes that had electrocardiograms available. Finally, 19 patients reported ICD 186 
shocks only at visits for which no device memory data was available. In total, 308 patients 187 
had shocks.  188 
There were 6,017 arrhythmic episodes in 388 patients for which ATP was delivered 189 
(1.37 episodes per patient year). There were 1162 hospitalizations in 589 patients reported.   190 
Association Between ICD Shock and Physical Activity 191 
Daily activity data were available for 2,555 patients. Average daily physical activity 192 
was 185.3 ± 119.4 minutes per day.  193 
Patient Activity Trends Over Time and the Acute Effects of Shock 194 
There was a clear rise in physical activity during the first 90 days post-implant (+88.6 195 
minutes/day, CI: 85.4 to 91.8, p<0.0001) followed by a gradual decline (-14.9 minutes/day 196 
between 3 and 24 months, CI: -17.7 to -12.1, p<0.0001). 197 
Pre-shock activity levels of patients that experienced ICD shock during follow up did 198 
not differ significantly from activity levels of patients who did not receive shocks (193.6 ± 199 
119.4 minutes/day vs 185.8 ± 119.0 minutes/day, p=0.61). Patients with a CRT-D device 200 
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were less active than ICD patients, 164.4 ± 110.7 versus 198.4 ± 122.6 minutes/day 201 
(p<0.0001; see Supplementary Figure S1 for activity values from baseline to 24 months). 202 
Corrected for device type there was no difference between primary and secondary prevention 203 
patients. Hospitalization was associated with a significant reduction in daily physical activity 204 
(75.3 ± 84.6 minutes/day in hospital compared to 185.9 ± 119.2 minutes/day out of hospital, 205 
p<0.0001).  206 
The acute effects of ICD shock on activity are illustrated in Figure 1A. The data show 207 
that activity was significantly reduced after an ICD shock (-23.7 minutes/day when corrected 208 
for device type, time since implant, and the effect of hospitalization, CI: -30.2 to -17.2, 209 
p<0.0001) and recovered as time since shock increased (at 30 days post-shock, activity 210 
increased +10.1 minutes/day, CI: 4.1 to 16.0, p=0.0010). Post-shock activity reduction did 211 
not differ significantly between shocks with a hospitalization and shocks without a 212 
hospitalization (22.9 minutes/day vs. 19.6 minutes/day; p=0.61, Supplemental Figure 2).  213 
Number of Prior Shocks  214 
Activity reduction was associated with the number of prior ICD shocks, with 21.1 215 
minutes/day decrease when there was exactly 1 prior shock, 27.4 minutes/day after 2-5 216 
shocks, and 33.8 minutes/day after more than 5 shocks (p=0.018).  217 
Appropriate vs. Inappropriate Shock 218 
Activity reduction did not differ significantly between appropriate and inappropriate 219 
shocks (24.6 minutes/day, CI: 17.9 to 31.2, vs 20.2 minutes/day, CI: 6.0 to 34.5; p=0.26, 220 
Supplemental Figure 3). 221 
Antitachycardia Pacing (ATP)  222 
Figure 1B illustrates physical activity in the days before and after low-voltage pacing 223 
therapy (ATP). Activity was significantly reduced after ATP (-5.8 minutes/day relative to the 224 
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patient’s overall average activity, CI: -11.4 to -0.13, p=0.045), although the magnitude of the 225 
effect is much smaller than for shocks. 226 
Association Between ICD Shock and Quality of Life  227 
Quality of life scores (EQ5D Health Score) before and after ICD shock are shown in 228 
Figure 2. Baseline average on the EQ5D Health Score was 66.8 ± 19.2. The EQ5D Health 229 
Score was lower for CRT-D patients than for ICD patients (64.8 ± 19.1 vs 67.9 ± 19.2, 230 
p<0.0001). Corrected for device type, there was no difference between primary and 231 
secondary prevention patients and there was also no difference in EQ5D Health Score at 232 
baseline between patients that did and did not experience subsequent ICD shock (67.5 ± 18.3 233 
vs 66.7 ± 19.3; p=0.50).  234 
Quality of Life Trends Over Time and the Acute Effects of Shock  235 
Follow-up Health Score assessments were generally higher than baseline (de novo 236 
implants +7.0 points at 12 months; CI: 6.1 to 7.9, p=0.004), however there were significant 237 
decreases during hospitalization (-7.6 points; CI: -10.3 to -4.9, p<0.0001) and when there had 238 
been any earlier shock (-3.6 points; CI: -5.1 to -2.1, p<0.0001, Table 2).  239 
The acute effects of ICD shock on quality of life were also examined by comparing 240 
the last assessment before and the first assessment after a patient’s first shock episode. These 241 
data demonstrated a significant decrease in overall Health Score (68.2 ± 19.3 vs 65.2 ± 20.5; 242 
p = 0.029). EQ5D subscale scores before and after shock are reported in Supplemental Table 243 
1. Shocks significantly impacted Anxiety/Depression, but not Mobility, Self-Care, Usual 244 
Activity, or Pain/Discomfort. Quality of life was also examined monthly for 6 months after 245 
the shock event (Figure 4 in the Data Supplement). Post-shock EQ5D Health Score increased 246 
as time since shock progressed, signifying improved perceived health (p=0.017). 247 
Number of Prior Shocks  248 
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The number of prior shocks was associated with the Health Score such that, more 249 
shocks were associated with worse quality of life (p=0.01). The Health Score was reduced by 250 
2.1 points when there was 1 prior shock, by 4.3 points after 2-5 shocks, and by 6.4 points 251 
after >5 shocks. 252 
Appropriate vs. Inappropriate Shock 253 
The decrease in Health Score was seen only after appropriate shocks (-3.9 points; 254 
p<0.0001); there was not a decrease after inappropriate shocks (-0.9 points; CI: -3.8 to 2.0, 255 
p=0.55).  256 
Association Between ICD Shock and Shock Anxiety  257 
Shock anxiety scores (FSAS scores) before and after ICD shock are presented in Figure 3. At 258 
baseline, the average FSAS score was 16.6 ± 8.0, comparable to existing norms.5 There were 259 
no differences between ICD and CRT-D patients, nor between primary and secondary 260 
prevention. No baseline differences in FSAS scores were found between patients with and 261 
without subsequent shock (16.9 ± 7.6 vs 16.6 ± 8.0; p=0.69). 262 
Shock Anxiety Trends Over Time and the Acute Effects of Shock 263 
Follow-up FSAS assessments were generally lower than baseline (-2.8 points; CI: -3.1 264 
to -2.5, p<0.0001) and not different during hospitalization (+1.0 points; CI: -0.4 to 2.3, 265 
p=0.17), but were significantly increased when there had been any earlier shock (+3.2 points; 266 
CI: 2.6 to 3.7, p<0.0001, Table 2).  267 
The acute effects of ICD shock on shock anxiety were examined monthly for 6 268 
months after the shock event (Figure 4). In patients with a prior ICD shock, proximity to the 269 
event was significantly associated with FSAS scores, such that greater time since shock was 270 
associated with lower FSAS scores and decreased shock anxiety (-0.4 points per months; CI: 271 
-0.5 to -0.3, p < 0.0001). However, even > 6 months after the ICD discharge, shock anxiety 272 
remained increased (+1.9 points; CI: 1.1 to 2.7, p<0.0001). 273 
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Number of Prior Shocks  274 
The number of prior shocks had a significant impact on the FSAS score (p=0.002), 275 
FSAS scores increased by 3.3 points when there was 1 prior shock, 2.4 points after 2-5 276 
shocks, and 5.3 points when there were >5 prior shocks. A higher number of shocks (1 shock 277 
vs. >5 shocks) was associated with a significant increase in shock anxiety (p=0.0074).  278 
Appropriate vs. Inappropriate Shock 279 
The increase in shock anxiety was larger after appropriate shocks compared to 280 
inappropriate shocks (3.3 vs 1.1 points; p=0.009), but was not significantly different when the 281 
patient was hospitalized (4.6 vs 3.0 points; p=0.11).  282 
Discussion 283 
This study is the first prospective examination of the acute and chronic effects of ICD 284 
shock on objective behaviors (i.e. accelerometer detected physical activity) and subjective 285 
quality of life outcomes (i.e. self-reported quality of life and shock anxiety) in a large, 286 
international cohort of ICD patients. The principal findings from this study are that ICD 287 
shock has immediate and long-term adverse effects on global and disease-specific quality of 288 
life. Furthermore, baseline device-detected daily physical activity was low in most ICD 289 
patients (approximately 3 hours per day) and significantly declined after ICD shock. Activity 290 
gradually increased as time since shock progressed and returned to pre-shock levels after 291 
approximately 90 days. 292 
 By integrating multiple diagnostic parameters to assess quality of life in ICD patients, 293 
the current study addresses major limitations of previously published trials. The Sudden 294 
Cardiac Death in Heart Failure Trial (SCD-HeFT) demonstrated the deleterious effect of ICD 295 
shock on quality of life in the month following a shock using a generic quality of life 296 
metric.12 Our study extends these findings by describing both the acute and long-term impact 297 
of shock on behavioral and psychological recovery in ICD patients. Notably, our analyses 298 
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also accounted for device type, ICD indication, device-delivered therapy (shock vs. low 299 
voltage pacing), hospitalization, and single vs. multiple ICD shocks. Collectively, these data 300 
suggest that declines in quality of life after ICD shock persist beyond 30 days post-shock and 301 
may be influenced by significant reductions in daily physical activity, increased general 302 
anxiety, and shock anxiety. Generic components of health-related quality of life including 303 
mobility, self-care, activity, and pain were not sensitive to these changes, suggesting that 304 
shock anxiety and device-based activity data may be more useful measures of ICD-specific 305 
outcomes.   306 
The current study builds on earlier work demonstrating the reliability, utility, and 307 
significance of device-detected activity data as a prognostic indicator of clinical outcomes.9, 308 
10, 13
 In a study of heart failure patients with implanted cardiac devices, Cowie et al. found 309 
low levels of device-detected activity to be independently associated with a 2.5-fold increase 310 
in risk for hospitalization within the next 30 days.13 Additionally, recent data from the 311 
ALTITUDE Activity Study demonstrated lower baseline physical activity was associated 312 
with a 40% absolute increase in mortality 4 years after implant.10 Low levels of baseline 313 
physical activity found in this study (185.3 ± 119.4 minutes per day) are comparable to 314 
activity data reported by Kramer et al. (107.5 ± 66.2 minutes per day). However, that study 315 
did not adjust for hospitalization in their activity analyses and thus, our findings provide 316 
important clarification of hospital vs. non-hospital activity data.  317 
Results from the current study also demonstrate the immediate and lasting effects of 318 
ICD shock on physical activity and illustrate the significant amount of time (approximately 3 319 
months) it takes patients to return to baseline levels of activity after ICD shock. Given the 320 
known associations between low levels of physical activity, psychological functioning, and 321 
adverse cardiac events, it is reasonable to assume that ICD patients who experience shock 322 
and a prolonged decline in physical activity may have an increased risk for hospitalization, 323 
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morbidity, and mortality. Whether device activity could serve as a behavioral “early warning” 324 
system to prevent adverse outcomes is unknown but potentially viable, and could be 325 
examined in future research. 326 
Limitations 327 
Several limitations should be considered when interpreting these findings. First, the 328 
use of self-reported measures is subject to multiple sources of bias including self-presentation 329 
bias, the effects of practice or fatigue, and regression to the mean. Second, ICD 330 
accelerometers do not provide information concerning activity intensity or type of movement. 331 
Third, participants in this study were enrolled in a clinical trial of a single vendor using one 332 
brand of ICDs. Moreover, there was no independent validity check on the accelerometer data 333 
but such data exists in the literature.11 Additionally, our sample included patients from the 334 
original Painfree SST trial with new implants, upgrades, and replacements and it is possible 335 
that device history or prior shock may have influenced study outcomes. However, we note 336 
that 67% of our sample was de novo implants. Finally, it is possible that the higher frequency 337 
of measurement of activity compared to FSAS and EQ5D measurement frequency 338 
contributed to the increased sensitivity to capture the effect of a shock. 339 
Conclusions 340 
This large prospective study of ICD patients demonstrated that ICD shock has 341 
immediate and long-term effects on objective and subjective indicators of health, including 342 
device measured physical activity, quality of life, and shock anxiety. These results lend 343 
further credibility to consideration of patient activity as an important quality of life outcome 344 
and support the need for further research and targeted patient and provider interventions to 345 
optimize clinical management.   346 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
15 
 
Acknowledgements: We are grateful to Dedra Fagan, of Medtronic, for editorial support. 347 
 348 
Funding: The PainFree SST study was funded by Medtronic plc (Minneapolis, MN). 349 
 350 
351 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
16 
 
References 352 
1. Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, Daubert JP, 353 
McNitt S, Andrews ML, Elkin AD, Multicenter Automatic Defibrillator Implantation 354 
Trial IIRG. Long-term clinical course of patients after termination of ventricular 355 
tachyarrhythmia by an implanted defibrillator. Circulation Dec 21 2004;110:3760-356 
3765. 357 
2. Cutitta KE, Woodrow LK, Ford J, Shea J, Fischer A, Hazelton G, Sears SF. 358 
Shocktivity: ability and avoidance of daily activity behaviors in ICD patients. J 359 
Cardiopulm Rehabil Prev Jul-Aug 2014;34:241-247. 360 
3. Sears SF, Kirian K. Shock and patient-centered outcomes research: is an ICD shock 361 
still a critical event? Pacing Clin Electrophysiol Dec 2010;33:1437-1441. 362 
4. Salmoirago-Blotcher E, Ockene IS. Methodological limitations of psychosocial 363 
interventions in patients with an implantable cardioverter-defibrillator (ICD) A 364 
systematic review. BMC Cardiovasc Disord Dec 29 2009;9:56. 365 
5. Kuhl EA, Dixit NK, Walker RL, Conti JB, Sears SF. Measurement of patient fears 366 
about implantable cardioverter defibrillator shock: an initial evaluation of the Florida 367 
Shock Anxiety Scale. Pacing Clin Electrophysiol Jun 2006;29:614-618. 368 
6. Sears SF, Whited A, Koehler J, Gunderson B. Examination of the differential impacts 369 
of antitachycardia pacing vs. shock on patient activity in the EMPIRIC study. EP 370 
Europace 2015;17:417-423. 371 
7. Auricchio A, Meijer A, Kurita T, Schloss E, Brinkman K, Claessens-van Ooijen M, 372 
Sterns L. Safety, efficacy, and performance of new discrimination algorithms to 373 
reduce inappropriate and unnecessary shocks: the PainFree SST clinical study design. 374 
Europace Oct 2011;13:1484-1493. 375 
8. Auricchio A, Schloss EJ, Kurita T, Meijer A, Gerritse B, Zweibel S, AlSmadi FM, 376 
Leng CT, Sterns LD, Investigators PS. Low inappropriate shock rates in patients with 377 
single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel 378 
suite of detection algorithms: PainFree SST trial primary results. Heart Rhythm May 379 
2015;12:926-936. 380 
9. Conraads VM, Spruit MA, Braunschweig F, Cowie MR, Tavazzi L, Borggrefe M, 381 
Hill MR, Jacobs S, Gerritse B, van Veldhuisen DJ. Physical activity measured with 382 
implanted devices predicts patient outcome in chronic heart failure. Circ Heart Fail 383 
Mar 01 2014;7:279-287. 384 
10. Kramer DB, Mitchell SL, Monteiro J, Jones PW, Normand SL, Hayes DL, Reynolds 385 
MR. Patient Activity and Survival Following Implantable Cardioverter-Defibrillator 386 
Implantation: The ALTITUDE Activity Study. J Am Heart Assoc May 15 2015;4. 387 
11. Vegh EM, Kandala J, Orencole M, Upadhyay GA, Sharma A, Miller A, Merkely B, 388 
Parks KA, Singh JP. Device-measured physical activity versus six-minute walk test as 389 
a predictor of reverse remodeling and outcome after cardiac resynchronization therapy 390 
for heart failure. Am J Cardiol May 01 2014;113:1523-1528. 391 
12. Mark DB, Anstrom KJ, Sun JL, Clapp-Channing NE, Tsiatis AA, Davidson-Ray L, 392 
Lee KL, Bardy GH, Sudden Cardiac Death in Heart Failure Trial I. Quality of life 393 
with defibrillator therapy or amiodarone in heart failure. N Engl J Med Sep 4 394 
2008;359:999-1008. 395 
13. Cowie MR, Sarkar S, Koehler J, Whellan DJ, Crossley GH, Tang WH, Abraham WT, 396 
Sharma V, Santini M. Development and validation of an integrated diagnostic 397 
algorithm derived from parameters monitored in implantable devices for identifying 398 
patients at risk for heart failure hospitalization in an ambulatory setting. Eur Heart J 399 
Aug 2013;34:2472-2480. 400 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
17 
 
Figure Legends 401 
Figure 1. Averaged daily activity in relation to time before or after ICD shock (panel A) or 402 
ATP therapy (panel B). The horizontal line represents the overall average activity excluding 403 
measurements from the first 90 days post-implant or within 90 days before and 90 days after 404 
a shock.  405 
 406 
Figure 2. Quality of life (EQ5D Health Score) at scheduled follow-up visits, before and after 407 
ICD shock. The horizontal line represents the average Health Score from scheduled follow-408 
up visits when there was no earlier shock.  409 
 410 
Figure 3. Shock anxiety (FSAS scores) before and after ICD shock. The increase of the score 411 
after a shock is significant (p<0.0001), indicating worse shock anxiety following ICD shock. 412 
The horizontal line represents the average FSAS score from scheduled follow-up visits when 413 
there was no earlier shock. 414 
 415 
Figure 4. FSAS score decreases when the ICD shock is longer ago, signifying lower anxiety 416 
(p<0.0001). The horizontal line represents the average FSAS score from scheduled follow-up 417 
visits when there was no earlier shock.  418 
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Tables 419 
Table 1: Patient Characteristics  420 
 421 
Patient Characteristics All patients 
(N = 2770) 
Any Shock 
(N = 308) 
Inappropriate 
Shock 
(N = 70) 
Demographics and Clinical 
Presentation 
   
Geography     
  North America 1129 (41%) 93 (30%) 18 (26%) 
  Europe 1056 (38%) 134 (44%) 28 (40%) 
  Other 585 (21%) 81 (26%) 24 (34%) 
Male 2200 (79%) 265 (86%) 55 (79%) 
Age (years) 65 ± 12 64 ± 13 62 ± 13 
LVEF (%) 32 ± 13 33 ± 14 36 ± 16 
QRS (ms) 126 ± 33 128 ± 33 121 ± 28 
Secondary prevention  847 (31%) 151 (49%) 23 (33%) 
NYHA class    
  I 419 (15%) 58 (19%) 14 (20%) 
  II 1104 (40%) 124 (40%) 28 (40%) 
  III 853 (31%) 85 (28%) 19 (27%) 
  IV 38 (1%) 4 (1%) 0 (0%) 
  No Heart Failure 354 (13%) 36 (12%) 8 (11%) 
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Patient Characteristics All patients 
(N = 2770) 
Any Shock 
(N = 308) 
Inappropriate 
Shock 
(N = 70) 
History    
Coronary artery disease 1745 (63%) 185 (60%) 30 (43%) 
Myocardial infarction 1048 (38%) 118 (38%) 14 (20%) 
Congestive heart failure 1060 (38%) 98 (32%) 19 (27%) 
Hypertension 1444 (52%) 145 (47%) 35 (50%) 
Valve dysfunction 697 (25%) 83 (27%) 14 (20%) 
Coronary artery bypass graft (CABG) 658 (24%) 75 (24%) 8 (11%) 
Previous device, any 923 (33%) 96 (31%) 22 (31%) 
Arrhythmias and Conduction Defects    
Atrial fibrillation 818 (30%) 119 (39%) 35 (50%) 
Ventricular tachycardia, (incl. non-
sustained) 
991 (36%) 171 (56%) 37 (53%) 
AV block 404 (15%) 45 (15%) 2 (3%) 
Left bundle branch block 699 (25%) 75 (24%) 16 (23%) 
Right bundle branch block 215 (8%) 35 (11%) 6 (9%) 
Device    
  CRT-D 1071 (39%) 113 (37%) 22 (31%) 
  DR ICD 948 (34%) 114 (37%) 26 (37%) 
  VR ICD 751 (27%) 81 (26%) 22 (31%) 
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Patient Characteristics All patients 
(N = 2770) 
Any Shock 
(N = 308) 
Inappropriate 
Shock 
(N = 70) 
Medication    
ACE-inhibitor or ARB 2133 (77%) 240 (78%) 58 (83%) 
Beta-Blocker 2370 (86%) 263 (85%) 63 (90%) 
Diuretic 1886 (68%) 206 (67%) 48 (69%) 
Statin 1673 (60%) 186 (60%) 35 (50%) 
Anti-Arrhythmic 519 (19%) 88 (29%) 13 (19%) 
Numbers are n (%) or mean ± standard deviation. 422 
Abbreviations: ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; 423 
AV: atrio-ventricular; CRT-D: cardiac resynchronization therapy defibrillator; DR-ICD: 424 
dual-chamber implantable cardioverter defibrillator; LVEF: left ventricular ejection fraction; 425 
NYHA: New York Heart Association; VR-ICD: single chamber implantable cardioverter 426 
defibrillator.  427 
  428 
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Table 2. The effect of hospitalization and ICD shock on EQ5D Health Score and FSAS  429 
 EQ5D Health Score  
value / change (CI) 
p-value FSAS 
value / change (CI) 
p-value 
Baseline ICD patients* 65.8 (64.9 to 66.7)  17.3 (16.9 to 17.6)  
CRT-D  - 2.3 (-3.5 to -1.1)  0.0001  -- (0.10)** 
Follow-up (12 months)*  + 7.0 (6.1 to 7.9) < 0.0001  - 2.8 (-3.1 to -2.5) < 0.0001 
In hospital  - 7.6 (-10.3 to -4.9) < 0.0001  -- (0.13)** 
Earlier shock  - 3.6 (-5.1 to -2.1) < 0.0001  + 3.2 (2.6 to 3.7) < 0.0001 
Abbreviations: CRT-D= Cardiac resynchronization therapy defibrillator; FSAS=Florida 430 
Shock Anxiety Scale; ICD=Implantable cardioverter defibrillator 431 
*For de novo implanted patients 432 
**Variable removed from final model; p-value from expanded model 433 
†For example, the average EQ5D Health Score of a CRT-D patient at 12 months after device 434 
implantation would be 65.8 – 2.3 + 7.0 = 70.5. If such patient had a prior shock and was 435 
hospitalized, the Health Score would be (3.6+7.6=) 11.2 points lower.  436 
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